{"url": "https://edition.cnn.com/2020/09/13/investing/gilead-immunomedics-acquisition/index.html", "title": "Gilead to acquire Immunomedics for $21 billion", "article": ["The deal with Immunomedics provides Gilead (GILD) with Trodelvy, an antibody drug for advanced triple-negative breast cancer. The drug was given accelerated FDA approval in April. Immunomedics will be acquired by $88 per share in cash -- more than double the $42.25 at which shares traded on Friday's close.", "\"This acquisition represents significant progress in Gilead's work to build a strong and diverse oncology portfolio,\" Gilead Chairman and CEO, Daniel O'Day said in a statement. \"Trodelvy is an approved, transformational medicine for a form of cancer that is particularly challenging to treat. We will now continue to explore its potential to treat many other types of cancer, both as a monotherapy and in combination with other treatments.\" ", "The deal is anticipated to close in the fourth quarter of 2020, according to the companies. The dealwill be funded by $15 billion in cash on hand and roughly $6 billion in newly issued debt, Gilead said. "]}